A Phase 3 interventional study of Vitrectomy in Retinal Detachment, sponsored by Asociación para Evitar la Ceguera en México. Terminated at 1 site in Mexico. Per ClinicalTrials.gov, last updated 2024-05-30.
Sponsored by Asociación para Evitar la Ceguera en México · Phase 3, Interventional, and Treatment
To investigate the feasibility and advantages of using pressurized perfluorocarbon liquid (PCL) perfusion to remove vitreous during suction-cutting 23 GA vitrectomy using a dual, dynamic drive (3D)technology, in complicated retinal detachment surgeries.
199 studies on the registry are indexed under Retinal Detachment; 29 are open to participants now.
This study's enrollment of 10 is below the median of 50 across 132 interventional studies indexed under Retinal Detachment.
Browse Retinal Detachment studies →Asociación para Evitar la Ceguera en México is the lead sponsor of 60 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
pressurized 23GA vitrectomy with a 3D system
Perfluorocarbon liquids consumption
Time frame: two months
This study is terminated, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Asociación para Evitar la Ceguera en México